65,437 trials
Brain Neoplasm
Primary: Haemodynamic Parameters at the Time of Emergence and Postextubation — 128.55; 132.34; 132.63; 134.29 mm Hg
Healthy Volunteers Diabetes Mellitus, Type 2 · Healthy Volunteers Overweight · Healthy Volunteers Obesity
Primary: Intensity of Injection Site Pain — 35.1; 4.4 score on a scale — p=<0.0001
Multiple Sclerosis · Fatigue
Primary: Change in Daily Fatigue Severity Score — -0.05; -0.05 score on a scale
Primary Open-angle Glaucoma and Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Week 2 — 18.19; 19.15 mmHg
Diabetes Mellitus · Hypertension · Hyperlipidemia
Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05
Diabetes Mellitus, Type 2 · Hypercholesterolemia
Primary: Change in Plasma LDL Cholesterol — -0.1 mmol/L
Vaginal Infection
Primary: Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit — 31; 29; 43 Participants — p=0.030
Mosquito-Borne Disease
Primary: AEs Grade 3 or Higher — 0.44; 0.65; 0.63 adverse events
Pulmonary Embolism
Primary: Right Ventricle/Left Ventricle (RV:LV) Ratio — 0.43 Change in RV/LV Diameter Ratio
Macular Degeneration
Primary: Percentage of Participants With Stable Vision — 97.6 percentage of participants
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs) — 60.2; 57.0 Percentage
Liver Cancer
Primary: Pharmacokinetics Profile-- Peak of Plasma Concentration (Dose-normalized) — 2.67; 3.68; 7.11; 0.08 ng/mL/mg — p=.036
Recurrent Oral Cavity Adenoid Cystic Carcinoma · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Objective Response According to RECIST 1.1 Criteria — 2; 27; 1 Participants
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12 — 21.8; 58.6; 64.4 percentage of…
Bleeding Active
Primary: Number of Participants With Hemostasis Achieved at Target Bleeding Site Within 5 Minutes After Application — 94; 109; 32; 15 Participants